264 related articles for article (PubMed ID: 32469082)
21. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
[TBL] [Abstract][Full Text] [Related]
22. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
Boiza-Sánchez M; Manso R; Balagué O; Chamizo C; Askari E; Salgado RN; Blas-López C; Aguirregoicoa-García E; Menárguez J; Santonja C; Adrados M; Limeres-González MÁ; Piris MÁ; Rodríguez-Pinilla SM
PLoS One; 2020; 15(11):e0241634. PubMed ID: 33180881
[TBL] [Abstract][Full Text] [Related]
23. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract][Full Text] [Related]
24. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
[TBL] [Abstract][Full Text] [Related]
25. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of
Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
[TBL] [Abstract][Full Text] [Related]
27. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.
Flümann R; Rehkämper T; Nieper P; Pfeiffer P; Holzem A; Klein S; Bhatia S; Kochanek M; Kisis I; Pelzer BW; Ahlert H; Hauer J; da Palma Guerreiro A; Ryan JA; Reimann M; Riabinska A; Wiederstein J; Krüger M; Deckert M; Altmüller J; Klatt AR; Frenzel LP; Pasqualucci L; Béguelin W; Melnick AM; Sander S; Montesinos-Rongen M; Brunn A; Lohneis P; Büttner R; Kashkar H; Borkhardt A; Letai A; Persigehl T; Peifer M; Schmitt CA; Reinhardt HC; Knittel G
Blood Cancer Discov; 2021 Jan; 2(1):70-91. PubMed ID: 33447829
[TBL] [Abstract][Full Text] [Related]
28. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
29. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.
Juskevicius D; Lorber T; Gsponer J; Perrina V; Ruiz C; Stenner-Liewen F; Dirnhofer S; Tzankov A
Leukemia; 2016 Dec; 30(12):2385-2395. PubMed ID: 27198204
[TBL] [Abstract][Full Text] [Related]
30. Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
Mishina T; Oshima-Hasegawa N; Tsukamoto S; Fukuyo M; Kageyama H; Muto T; Mimura N; Rahmutulla B; Nagai Y; Kayamori K; Hino Y; Mitsukawa S; Takeda Y; Ohwada C; Takeuchi M; Tsujimura H; Iseki T; Nakaseko C; Ikeda JI; Itami M; Yokote K; Ohara O; Kaneda A; Sakaida E
Br J Haematol; 2021 Dec; 195(5):731-742. PubMed ID: 34378195
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
32. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis.
Cristian M; Așchie M; Mitroi AF; Deacu M; Boșoteanu M; Bălțătescu GI; Stoica AG; Nicolau AA; Enciu M; Crețu AM; Caloian AD; Orășanu CI; Poinăreanu I
Medicine (Baltimore); 2024 Feb; 103(6):e36269. PubMed ID: 38335426
[TBL] [Abstract][Full Text] [Related]
33. Genomic Alterations and MYD88
Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
[TBL] [Abstract][Full Text] [Related]
34. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
35. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
[TBL] [Abstract][Full Text] [Related]
37. Mutational landscape of high-grade B-cell lymphoma with
Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
[TBL] [Abstract][Full Text] [Related]
38. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
39. Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM; Quivoron C; Sarkozy C; Danu A; Lazarovici J; Saleh K; El-Dakdouki Y; Goldschmidt V; Bigenwald C; Dragani M; Bahleda R; Baldini C; Arfi-Rouche J; Martin-Romano P; Tselikas L; Gazzah A; Hollebecque A; Lacroix L; Ghez D; Vergé V; Marzac C; Cotteret S; Rahali W; Soria JC; Massard C; Bernard OA; Dartigues P; Camara-Clayette V; Ribrag V
Am J Hematol; 2023 Apr; 98(4):645-657. PubMed ID: 36606708
[TBL] [Abstract][Full Text] [Related]
40. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
